Trial Profile
Security of CIMAvax-EGF(R) vaccine for the treatment of patients with NSCLC in advanced stages. Effectiveness exploration according to baseline concentrations of EGF. phase IV
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Nov 2022
Price :
$35
*
At a glance
- Drugs BV NSCLC 001 (Primary) ; Cyclophosphamide
- Indications Carcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- 01 Jun 2021 Status has been changed to completed, according results published in the Cancer Immunology Immunotherapy.
- 01 Jun 2021 Results published in the Cancer Immunology Immunotherapy
- 26 Aug 2016 New trial record